Format

Send to

Choose Destination
Hamostaseologie. 2017 Aug 7;37(3):186-195. doi: 10.5482/HAMO-16-07-0019. Epub 2016 Nov 29.

Management of chronic hepatitis C in 2017.

Author information

1
Prof. Dr. med. Jean-François Dufour, MD, Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Freiburgstrasse, 3010 Bern, Switzerland, Phone: +41316328026; Fax: +41316327489, E-mail: jean-francois.dufour@insel.ch.

Abstract

Hepatitis C virus (HCV) represents one of the most common aetiologies of chronic liver disease and causes a major global health burden. Globally an estimated 80 million people are chronically infected, but the majority of whom is still undiagnosed. Prior to the discovery of the virus in 1989 a significant number of patients were exposed and consecutively infected with HCV via contaminated transfusions, as it is a blood-borne disease. Chronic HCV infection pursues a progressive course that ultimately results in the development of cirrhosis, liver failure and hepatocellular carcinoma (HCC), if left untreated. The efficiency and tolerability of therapeutical approaches improved considerably with the development of direct-acting antivirals (DAA). The majority of patients treated with the recommended DAA combinations can be cured, which is reflected in achievement of sustained virological response (SVR). This review is intended to provide guidance in the management of patients with chronic hepatitis C, including recommendations for adequate screening, diagnostic procedures, clinical care, treatment and follow-up strategies.

KEYWORDS:

direct-acting antivirals; hepatitis C Virus; risk factors; sustained virological response

PMID:
27896359
DOI:
10.5482/HAMO-16-07-0019

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center